Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CAD | P27708 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294810 | 1.00 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL18735207 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL8752060 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL8751980 | 0.86 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL19176028 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL21554072 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953807 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953811 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953812 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL6470507 | 0.85 | KDM4E (0.38) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030095959-A1 | Topical skin composition | ACCESS BUSINESS GROUP INTERNATIONAL LLC. | 2003-05-22 | — | — | US | claimed |
| EP-0716601-B1 | USE OF N,S-DIACETYLCYSTEINE-ETHYLESTER (DACEE) FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | LUDWIG WEISS DR (DE) | 2000-06-28 | — | — | EP | claimed |
| US-6045832-A | ADMINISTERING DOSAGE OF N,S-DIACETYLCYSTEINE ETHYL ESTER (DACEE) IN A CARRIER FOR INHIBITING PROPAGATION OF HEPATITIS VIRUS | LUDWIG WEISS (DE) | 2000-04-04 | — | — | US | claimed |
| US-20080124409-A1 | Topical Skin Compositions, Their Preparation, and Their Use | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080081034-A1 | Topical Skin Compositions, Their Preparation, and Their Use | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2008-04-03 | — | — | US | disclosed |
| US-20080081082-A1 | Topical Skin Compositions, Their Preparation, and Their Use | ACCESS BUSINES GROUP INTERNATIONAL LLC | 2008-04-03 | — | — | US | disclosed |
| US-20070003536-A1 | Topical skin compositions, their preparation, and their use | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2007-01-04 | — | — | US | disclosed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030095959-A1 | Topical skin composition | ACCESS BUSINESS GROUP INTERNATIONAL LLC. | 2003-05-22 | — | — | US | disclosed |
| US-6426370-B1 | IN CELL-FREE ENVIRONMENT SUCH AS BLOOD, CELL CULTURE LIQUIDS AND NUTRIENT MEDIA, OR THE SURFACES OF PLANTS OR ANIMALS; N-ACETYL CYSTEINE FOR EXAMPLE | HOFSCHNEIDER PETER (DE) | 2002-07-30 | — | — | US | disclosed |
| US-20020040057-A1 | USE OF THIOL COMPOUNDS IN VIRAL INACTIVATION | HOFSCHNEIDER PETER (DE) | 2002-04-04 | — | — | US | disclosed |
| US-6045832-A | ADMINISTERING DOSAGE OF N,S-DIACETYLCYSTEINE ETHYL ESTER (DACEE) IN A CARRIER FOR INHIBITING PROPAGATION OF HEPATITIS VIRUS | LUDWIG WEISS (DE) | 2000-04-04 | — | — | US | disclosed |
| US-6045832-A | ADMINISTERING DOSAGE OF N,S-DIACETYLCYSTEINE ETHYL ESTER (DACEE) IN A CARRIER FOR INHIBITING PROPAGATION OF HEPATITIS VIRUS | LUDWIG WEISS (DE) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081034-A1 | Topical Skin Compositions, Their Preparation, and Their Use | COL14A1, MMP8, MMP1 | CYP1A2 597/4885CYP2C9 1114/4885CYP2C19 937/4885 |
| US-20080124409-A1 | Topical Skin Compositions, Their Preparation, and Their Use | COL14A1, MMP8, MMP1 | CYP1A2 597/4885CYP2C9 1114/4885CYP2C19 937/4885 |
| US-20030095959-A1 | Topical skin composition | CUTA, S100A4, KRT18 | CYP1A2 1425/4885CYP2C9 3890/4885CYP2C19 3377/4885 |
| US-20070003536-A1 | Topical skin compositions, their preparation, and their use | COL14A1, MMP8, MMP1 | CYP1A2 597/4885CYP2C9 1114/4885CYP2C19 937/4885 |
| US-20080081082-A1 | Topical Skin Compositions, Their Preparation, and Their Use | COL14A1, MMP8, MMP1 | CYP1A2 597/4885CYP2C9 1114/4885CYP2C19 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.